NanoSmart and UCLA hook up to target cancer

California drug delivery company NanoSmart Pharmaceuticals has hooked up with the University of California Los Angeles (UCLA) to develop targeted drugs for cancer and other serious life-threatening diseases. NanoSmart's delivery system uses a combination of autoimmune antibodies and liposomes to target tumors and deliver FDA-approved cancer drugs. The technique has a number of advantages--it cuts the side effects of drugs that can be toxic, and reduces development time by using drugs already on the market and with a history of safety and efficacy. This follows an agreement signed in November 2011 with the Children's Hospital Los Angeles to use its drug delivery technology for drugs against a form of childhood cancer called Ewing's sarcoma. Press release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…